In Vitro Endothelial Cell Proliferation Assay Reveals Distinct Levels of Proangiogenic Cytokines Characterizing Sera of Healthy Subjects and of Patients with Heart Failure
Figure 5
Analysis of in vitro endothelial cell proliferation in relationship to clinical parameters. In (a), distribution of NYHA classes (I-II and III-IV) within the high/low endothelial cell proliferation clusters of HF patients. In (b), occurrence of clinical events experienced by HF patients in two years of follow-up within the high/low endothelial cell proliferation clusters. In (a) and (b), data are expressed as percentage of HF patients.
